Such findings suggest that differences in beta-blocker survival advantage observed in clinical trials could be significantly influenced by inclusion of varying geographic populations. Genetic diversity is highly recommended in the relevance of cardiovascular interpretation and trials of results. BEST included a prospectively-designed DNA substudy that recognized a subgroup of approximately 47 % of participants who had the Very Favorable response genotype. This genotype subgroup of BEST was when compared to overall study cohorts. Comparisons were not prospectively defined during the randomized trials. There is no adjustment for distinctions in baseline features of the trial populations.Acacia subsidiary receives patents for wifi physiological monitoring technology Acacia Research Corporation announced today that a subsidiary has acquired 11 patents for wireless physiological monitoring technology. ‘Acacia is quickly becoming the first choice in technology licensing and we continue to grow our base of future revenues with the addition of brand-new patent portfolios,’ concluded Mr. Ryan. This patented technology generally pertains to the wireless transmission of physiological data such as heart blood and rate pressure.